SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

NCT07470840 PHASE2 NOT_YET_RECRUITING

To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.

Details

Lead sponsor	Fujian Cancer Hospital
Phase	PHASE2
Status	NOT_YET_RECRUITING
Enrolment	27
Start date	Mon Feb 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 01 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Locally Advanced or Metastatic Renal Cell Carcinoma

Interventions

• Stereotactic Body Radiation Therapy (SBRT)
• Anlotinib
• Bemarituzumab

Countries

China